Company Short-Term Debts: Apollomics, Inc. (APLM)

Apollomics, Inc. (APLM) relies on outsourced synthesis and testing, retaining only patent rights. The synergy between Western technologies and the Chinese market accelerates the launch of therapies for rare tumors. However, the lack of revenue makes the company dependent on investments, as confirmed by its short-term debt portfolio. The value of 0.00 shapes the current metric, demonstrating the dynamics of annual obligations.

Short-term debts measure the aggregate of obligations with a maturity of up to one year, determining current liquidity and the issuer's ability to service accounts payable without raising external capital. By analyzing the structure of short-term liabilities, an investor assesses the financial stability of Apollomics, Inc. (APLM) amid stringent regulatory oversight from the FDA and NMPA, where the scaling pace of targeted therapy depends directly on the availability of free cash flow.